ALLMedicine™ Neuromyelitis Optica Center
Research & Reviews 1,625 results
https://doi.org/10.1186/s12883-022-02698-y 10.1016/j.autrev.2013.10.003 10.1001/jamaneurol.2014.2633 10.1007/s10072-021-05427-4 10.1016/j.radcr.2021.09.033 10.7759/cureus.17961 10.1212/WNL.0000000000001729 10.1177/1352458517703803 10.1016/j.msard.2021.103394 10.1212/WNL.0b013e31825fdead 10.1016/j.msard.2016.11.009
BMC Neurology; Lohmann L, Glaser F et. al.
May 19th, 2022 - Since the beginning of the COVID-19 pandemic and development of new vaccines, the issue of post-vaccination exacerbation or manifestation of demyelinating central nervous system (CNS) disorders has gained increasing attention. We present a case of...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106400
The Journal of Pediatrics; Aubart M, Roux CJ et. al.
May 17th, 2022 - To describe neurologic, radiologic and laboratory features in children with central nervous system (CNS) inflammatory disease complicating SARS-CoV-2 infection. We focused on CNS inflammatory diseases in children referred from 12 hospitals in the ...
https://doi.org/10.1016/j.jocn.2022.05.002
Journal of Clinical Neuroscience : Official Journal of Th... Duan Z, Feng J
May 16th, 2022 - The neutrophil-to-lymphocyte ratio (NLR) is a biomarker for evaluating disease activity in systemic autoimmune diseases. However, few studies have discussed NLR changes in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Th...
https://doi.org/10.1016/j.msard.2022.103772
Multiple Sclerosis and Related Disorders; Yamamura T, Araki M et. al.
May 11th, 2022 - Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.|2022|Yamamura T,Araki M,Fujihara K,Okuno T,Misu T,|
https://clinicaltrials.gov/ct2/show/NCT01623076
May 11th, 2022 - This study seeks to determine the biologic causes of inflammation in patients with Neuromyelitis Optica (NMO), Transverse Myelitis (TM), optic neuritis (ON), related conditions and healthy controls. While patients will be treated according to deci...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515040
Neurology Wingerchuk DM, Banwell B et. al.
Jun 21st, 2015 - Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord i...
Drugs 3 results see all →
Clinicaltrials.gov 25 results
https://clinicaltrials.gov/ct2/show/NCT01623076
May 11th, 2022 - This study seeks to determine the biologic causes of inflammation in patients with Neuromyelitis Optica (NMO), Transverse Myelitis (TM), optic neuritis (ON), related conditions and healthy controls. While patients will be treated according to deci...
https://clinicaltrials.gov/ct2/show/NCT05154734
May 10th, 2022 - The investigators primarily aim to observe the time to first relapse from initiation of belimumab treatment. The secondary outcomes are to determine: The safety profile of belimumab in participants with NMO and whether belimumab improves Expanded ...
https://clinicaltrials.gov/ct2/show/NCT04614454
Apr 15th, 2022 - Neuromyelitis optica spectrum disorder (NMOSD) is a chronic relapsing autoimmune disease of the central nervous system (CNS) that preferentially targets the optic nerves and spinal cord, leading to paralysis, blindness and death. NMOSD is a rare d...
https://clinicaltrials.gov/ct2/show/NCT04629274
Mar 31st, 2022 - This is a fundamental, prospective, multi-centres, interventional non-comparative study without the administration of a study product to patients. The objective is to test in vitro the binding of different Imotopes® to class II HLA antigens on per...
https://clinicaltrials.gov/ct2/show/NCT02028884
Feb 17th, 2022 - The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NM...
News 108 results
https://www.medscape.com/viewarticle/970351
Mar 15th, 2022 - Among patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) receiving ocrelizumab or rituximab, B cell depletion appears to last well past the 6-month dosing regimen typically used with these drugs. The results, ...
https://www.medscape.com/viewarticle/962984
Nov 15th, 2021 - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the immunosuppressant inebilizumab (Uplizna, Horizon Therapeutics) for adults with neuromyelitis optica spectrum disorder ...
https://www.medscape.com/viewarticle/961634
Oct 26th, 2021 - A new indirect comparison of the three new FDA-approved treatment options for adults with aquaporin4+ (AQP4+) neuromyelitis optica spectrum disorder (NMOSD), has suggested that eculizumab is far more effective than the other two agents in preventi...
https://www.medscape.com/viewarticle/956124
Aug 6th, 2021 - Differences in lesion evolution may help neurologists distinguish between multiple sclerosis (MS) and other demyelinating disorders in new findings that may help explain differences in disease course, particularly progressive disability in MS. Res...
https://www.medscape.com/viewarticle/949488
Apr 17th, 2021 - Black patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to common MS treatment compared to their White peers, new research suggests. In a study of almost 200 patients, Black participant...
